Importantly, combination treatment with hnCD16FR-iNK cells and anti-CD20 mAb exhibited more potent anti-tumor effects, controlling tumor expansion (Fig. 6B, C) and prolonging survival (Fig. 6D) more than Control iNK cells co-administered with anti-CD20 mAb. This evidence concerns the gene MS4A1 and neoplasm.